{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:04:08Z","timestamp":1781298248816,"version":"3.54.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Proton pump inhibitors (PPIs) are commonly used among these patients to prevent upper gastrointestinal bleeding (UGIB) in anticoagulated patients. However, their clinical benefits among patients receiving OACs with a history of UGIB remain inconclusive. This study aimed to summarize the clinical benefits of PPIs for the secondary prevention of recurrent UGIB among patients using OACs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search was performed in PubMed, EMBASE, Cochrane, and Scopus databases for clinical studies conducted among patients receiving OACs with PPIs and a history of UGIB. The primary outcome was the recurrent UGIB, analysed using a random-effect model. Heterogeneity was assessed by the I2-statistic. The quality of studies was assessed by the Newcastle-Ottawa Scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings and conclusions<\/jats:title>\n                    <jats:p>Four studies with a total of 67\u2009148 participants were included. Of those, three were conducted among patients with atrial fibrillation and one among unspecified patients. Our meta-analysis indicated that PPIs were associated with a lower risk of recurrent UGIB with a hazard ratio (HR) of 0.67 (95%CI; 0.58\u20130.76, I2\u2009=\u20098.9%) compared with no PPIs for patients receiving oral anticoagulants. Our subgroup analysis using comparators showed the robustness of the main findings. The HR of PPIs for recurrent UGIB in patients receiving vitamin K antagonists and direct oral anticoagulants compared with no PPI were 0.67 (95%CI; 0.54\u20130.80, I2\u2009=\u20090.0%) and 0.63 (95%CI; 0.52\u20130.74, I2\u2009=\u20090.0%), respectively. PPIs could potentially reduce the risk of recurrent UGIB. Clinicians might consider using PPIs for secondary prevention among patients receiving OAC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijpp\/riaf078","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T11:37:39Z","timestamp":1754998659000},"page":"229-234","source":"Crossref","is-referenced-by-count":1,"title":["Potential clinical benefits of proton pump inhibitors for secondary prevention of recurrent bleeding among patients with upper gastrointestinal bleeding receiving oral anticoagulants: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2629-4514","authenticated-orcid":false,"given":"Sinwisuth","family":"Sutheechai","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University , Suthep Road, Suthep, Mueang, Chiang Mai 50200 ,","place":["Thailand"]},{"name":"Pharmaceutical Care Training Center, Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Suthep Road, Suthep, Mueang, \u00a0 Chiang Mai 50200 ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2278-4099","authenticated-orcid":false,"given":"Buntitabhon","family":"Sirichanchuen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University , Suthep Road, Suthep, Mueang, Chiang Mai 50200 ,","place":["Thailand"]},{"name":"Center for Medical and Health Technology Assessment (CM-HTA), Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University , Suthep Road, Suthep, Mueang, Chiang Mai 50200 ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2977-3408","authenticated-orcid":false,"given":"Natapohn","family":"Chaipichit","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University , Suthep Road, Suthep, Mueang, Chiang Mai 50200 ,","place":["Thailand"]},{"name":"Center for Medical and Health Technology Assessment (CM-HTA), Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University , Suthep Road, Suthep, Mueang, Chiang Mai 50200 ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6040-0098","authenticated-orcid":false,"given":"Witoo","family":"Dilokthornsakul","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University , Suthep Road, Suthep, Mueang, Chiang Mai 50200 ,","place":["Thailand"]},{"name":"Center for Medical and Health Technology Assessment (CM-HTA), Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University , Suthep Road, Suthep, Mueang, Chiang Mai 50200 ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"2026061216442179500_ref1","doi-asserted-by":"publisher","first-page":"e3412","DOI":"10.1136\/bmj.e3412","article-title":"Management of acute upper gastrointestinal bleeding: summary of NICE guidance","volume":"344","author":"Dworzynski","year":"2012","journal-title":"BMJ"},{"key":"2026061216442179500_ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12113678","article-title":"A review of risk scores within upper gastrointestinal bleeding","volume":"12","author":"Orpen-Palmer","year":"2023","journal-title":"J Clin Med"},{"key":"2026061216442179500_ref3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.giec.2015.02.010","article-title":"Epidemiology and risk factors for upper gastrointestinal bleeding","volume":"25","author":"Tielleman","year":"2015","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"2026061216442179500_ref4","article-title":"Causes of upper gastrointestinal bleeding in adults","author":"Rockey"},{"key":"2026061216442179500_ref5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.amsu.2021.102958","article-title":"The mortality rate among patients with acute upper GI bleeding (with\/without EGD) at Aleppo University hospital: a retrospective study","volume":"71","author":"Aljarad","year":"2021","journal-title":"Ann Med Surg (Lond)"},{"key":"2026061216442179500_ref6","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.gtc.2014.08.001","article-title":"Epidemiology and diagnosis of acute nonvariceal upper gastrointestinal bleeding","volume":"43","author":"Rotondano","year":"2014","journal-title":"Gastroenterol Clin N Am"},{"key":"2026061216442179500_ref7","doi-asserted-by":"publisher","first-page":"103252","DOI":"10.1016\/j.amsu.2022.103252","article-title":"The risk factors for the recurrent upper gastrointestinal hemorrhage among acute peptic ulcer disease patients in Syria: a prospective cohort study","volume":"74","author":"Bitar","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"2026061216442179500_ref8","first-page":"169","article-title":"The role of proton pump inhibitors in the Management of Upper Gastrointestinal Disorders","volume":"14","author":"Ali Khan","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"2026061216442179500_ref9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40256-023-00582-9","article-title":"Management of Gastrointestinal Bleeding and Resumption of oral anticoagulant therapy in patients with atrial fibrillation: a multidisciplinary discussion","volume":"23","author":"Martin","year":"2023","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026061216442179500_ref10","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"key":"2026061216442179500_ref11","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"2026061216442179500_ref12","volume-title":"The Newcastle Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses","author":"Wells"},{"key":"2026061216442179500_ref13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/17423953221089309","article-title":"Systematic review on physical function, activities of daily living and health-related quality of life in COVID-19 survivors","volume":"19","author":"Oliveira Almeida","year":"2023","journal-title":"Chronic Illn"},{"key":"2026061216442179500_ref14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1572-0241.2006.01062.x","article-title":"Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants","volume":"102","author":"Lanas","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"2026061216442179500_ref15","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s10557-021-07170-6","article-title":"Proton pump inhibitor Co-therapy in patients with atrial fibrillation treated with oral anticoagulants and a prior history of upper gastrointestinal tract bleeding","volume":"36","author":"Lee","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026061216442179500_ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h5876","article-title":"Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: Nationwide cohort study","volume":"351","author":"Staerk","year":"2015","journal-title":"BMJ"},{"key":"2026061216442179500_ref17","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.cgh.2023.12.022","article-title":"Reduction of upper gastrointestinal bleeding risk with proton pump inhibitor therapy in Asian patients with atrial fibrillation receiving direct oral anticoagulant: a Nationwide population-based cohort study","volume":"22","author":"Lee","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061216442179500_ref18","doi-asserted-by":"publisher","first-page":"4676","DOI":"10.1111\/bcp.15478","article-title":"Protective effect of proton-pump inhibitor against gastrointestinal bleeding in patients receiving oral anticoagulants: a systematic review and meta-analysis","volume":"88","author":"Ahn","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2026061216442179500_ref19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4068\/cmj.2023.59.2.115","article-title":"Adverse effects associated with long-term use of proton pump inhibitors","volume":"59","author":"Maideen","year":"2023","journal-title":"Chonnam Med J"},{"key":"2026061216442179500_ref20","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1097\/MJT.0000000000000599","article-title":"The impact of proton pump inhibition on dabigatran levels in patients with atrial fibrillation","volume":"26","author":"Bolek","year":"2019","journal-title":"Am J Ther"},{"key":"2026061216442179500_ref21","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/fcp.12154","article-title":"In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors","volume":"29","author":"Ollier","year":"2015","journal-title":"Fundam Clin Pharmacol"},{"key":"2026061216442179500_ref22","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s11239-018-1748-5","article-title":"Does proton pump inhibition change the on-treatment anti-Xa activity in xabans-treated patients with atrial fibrillation?","volume":"47","author":"Bolek","year":"2019","journal-title":"A pilot study J Thromb Thrombolysis"},{"key":"2026061216442179500_ref23","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/FJC.0b013e31822f6c2b","article-title":"Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban","volume":"58","author":"Moore","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026061216442179500_ref24","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.amjcard.2013.10.044","article-title":"Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation","volume":"113","author":"Qureshi","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026061216442179500_ref25","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2026061216442179500_ref26","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2026061216442179500_ref27","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"2026061216442179500_ref28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5009\/gnl19009","article-title":"The role of acid suppressants in the prevention of anticoagulant-related gastrointestinal bleeding: a systematic review and meta-analysis","volume":"14","author":"Bang","year":"2020","journal-title":"Gut Liver"},{"key":"2026061216442179500_ref29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4292\/wjgpt.v5.i2.57","article-title":"Histamine2-receptor antagonists: rapid development of tachyphylaxis with repeat dosing","volume":"5","author":"McRorie","year":"2014","journal-title":"World J Gastrointest Pharmacol Ther"}],"container-title":["International Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijpp\/article-pdf\/34\/3\/229\/64230992\/riaf078.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijpp\/article-pdf\/34\/3\/229\/64230992\/riaf078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T20:44:28Z","timestamp":1781297068000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijpp\/article\/34\/3\/229\/8249976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9,9]]},"published-print":{"date-parts":[[2026,6,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ijpp\/riaf078","relation":{},"ISSN":["0961-7671","2042-7174"],"issn-type":[{"value":"0961-7671","type":"print"},{"value":"2042-7174","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2025,9,9]]}}}